Bristol-Myers Squibb (BMY) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive — consensus is a manageable bar and the growth portfolio has consistently beaten expectations — but the single biggest swing factor is whether the Eliquis inventory reversal (flagged on the Q1 call) creates a visible revenue headwind that spooks the market even if underlying demand is healthy.

Heading into Q2 2026, BMY's consensus revenue estimate of ~$11.7B represents a modest ~4.5% year-over-year step-up from Q2 2025's $12.3B actual, a bar that looks achievable given the growth portfolio's sustained momentum. Management explicitly guided toward the upper end of full-year 2026 ranges on the Q1 call and reiterated that confidence at the Goldman Sachs Healthcare Conference in June, signaling no deterioration in tone. Estimate revisions have been broadly stable-to-slightly-higher since the Q1 print, with non-GAAP EPS consensus edging up from ~$1.59 to ~$1.60, suggesting the Street is not aggressively de-risking the quarter. The stock has re-rated meaningfully since last earnings (+4.1% vs. XLV +13.9% since April 30), trading at ~10x NTM P/E — still a wide discount to large-cap pharma peers — implying the market has not fully priced in a beat. The key wildcard is the Eliquis inventory build reversal that management pre-announced for Q2: a Q1 wholesaler inventory build driven by the U.S. price reduction is expected to unwind in Q2, which could suppress reported Eliquis revenue even if underlying patient demand remains strong; how management frames this dynamic on the call will likely determine the stock's reaction more than the headline EPS number.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus sets a manageable bar on revenue (~$11.7B, +4.5% YoY) and non-GAAP EPS (~$1.60), but the growth portfolio trajectory — particularly Camzyos, Breyanzi, and Cobenfy — is the bigger swing factor; Eliquis reported revenue may disappoint on the inventory reversal even as demand holds.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures as of July 29, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters)

Total Revenue

Non-GAAP EPS (Diluted)

BMY has beaten consensus revenue estimates in each of the last 8 quarters, with an average revenue surprise of ~5.3% and an average non-GAAP EPS surprise of ~20% — a remarkably consistent track record that sets a high implicit expectation for Q2 2026.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Full-year 2026 guidance was reaffirmed at Q1 earnings with management explicitly tracking toward the upper end of both revenue and EPS ranges; no formal guidance revision has been issued since, and tone at the June Goldman Sachs conference remained constructive.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have drifted modestly higher since the Q1 print across all key KPIs, confirming the Street is incrementally more constructive — not de-risking — heading into Q2; the growth portfolio consensus has risen ~$440M since the post-Q1 baseline, suggesting analysts are giving credit to the commercial momentum management highlighted.

Estimates have been broadly stable-to-slightly-higher since the Q1 print, with the growth portfolio showing the most meaningful upward revision (+6.7% for Q2 2026 vs. the post-Q1 baseline), consistent with management's upper-end guidance tracking commentary. The Eliquis Q2 consensus of $3.97B already reflects the anticipated inventory reversal headwind flagged on the Q1 call.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: BMY has lagged XLV meaningfully since the Q1 print (+4.1% vs. +13.9% for XLV), with the stock's underperformance driven primarily by multiple compression relative to the sector rather than estimate cuts — suggesting the market is discounting pipeline execution risk rather than near-term earnings risk. The stock's 12-month re-rating (+32.9%, driven ~29% by multiple expansion) shows improving sentiment, but the NTM P/E of ~10x remains a wide discount to peers.

BMY vs. XLV (Health Care Select Sector SPDR ETF) vs. S&P 500 (SPY) — Indexed to 100 at April 30, 2026 (Q1 2026 earnings date). Source: Yahoo Finance / Stock Price Data.

Sector ETF used: XLV (Health Care Select Sector SPDR ETF) — appropriate for BMY's large-cap diversified biopharmaceutical profile.

Performance summary (April 30 – July 29, 2026): BMY +4.1% | XLV +13.9% | SPY +1.5%. BMY's underperformance vs. XLV reflects sector rotation into healthcare names with cleaner near-term catalysts (e.g., GLP-1 beneficiaries), while BMY's binary late-2026 pipeline readouts (milvexian AFib, Cobenfy ADEPT, admilparant IPF) keep a risk premium embedded in the stock. The 12-month stock performance decomposition shows the +32.9% gain was driven predominantly by EV/EBITDA multiple expansion (+21.4%) from a deeply depressed base, with the NTM EV/EBITDA now at 8.3x vs. 6.8x a year ago — still well below large-cap pharma peers.

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the Hengrui strategic collaboration (May 12), which represents one of the largest early-stage BD structures BMY has executed and validates management's stated BD urgency; the iberdomide PDUFA date of August 17 is the next near-term binary catalyst.

• May 12, 2026 — Hengrui Pharma Strategic Collaboration Announced. BMY announced a major collaboration covering oncology, hematology, and immunology assets across both companies. Structure includes four Hengrui oncology/hematology assets, four BMY immunology assets, and five jointly developed programs. BMY obtains exclusive worldwide rights to Hengrui assets ex-China; deal subject to antitrust review and expected to close Q3 2026. Implication: Validates management's 'no go-slow' BD posture and adds early/mid-stage pipeline depth without large upfront cash outlay.
• May 8, 2026 — Annual Meeting: Shareholders Back Management. Shareholders approved key management proposals and rejected an independent board chair mandate. Implication: Governance stability; no activist overhang heading into a critical pipeline readout year.
• June 9, 2026 — Goldman Sachs Healthcare Conference. CMO Cristian Massacesi and IR Head Chuck Triano confirmed business continues to perform well, growth portfolio delivering, and company tracking toward upper end of guidance. Milvexian AFib readout reaffirmed for Q4 2026. ADEPT-2 confirmed restarted after prior executional issues. Admilparant IPF readout guided for year-end 2026; PPF a few months later (early 2027). Implication: No negative pre-announcements; tone constructive and consistent with Q1 call.
• PDUFA Date: August 17, 2026 — Iberdomide (Relapsed/Refractory Multiple Myeloma). FDA accepted filing with breakthrough therapy designation and priority review. Management expects this to be the first NDA approved based on MRD negativity data. Implication: Near-term binary catalyst; approval would add a commercial-stage CELMoD asset and validate the platform ahead of mezigdomide and golcadomide.
• Q1 2026 Pipeline Highlights (Reported April 30): Mezigdomide SUCCESSOR-2 Phase III interim data positive (meaningful PFS improvement in R/R MM); Iza-bren positive Phase III interim data in TNBC and esophageal SCC (China studies); Sotyktu approved in psoriatic arthritis; Opdivo approved for two new classical Hodgkin Lymphoma indications; Camzyos positive Phase III data in adolescents with obstructive HCM; Reblozyl positive Phase II data in Alpha Thalassemia. Implication: Broad pipeline execution across multiple franchises reduces single-asset dependency.
• July 7, 2026 — Barron's Article: BMY Highlighted as Dividend Buy. Barron's cited BMY (alongside Medtronic) as a preferred healthcare dividend stock vs. Pfizer, noting improving fundamentals and pipeline optionality. Implication: Incremental positive sentiment; income-oriented investors may provide a valuation floor.
• Camzyos Competitive Dynamics: Aficamten (Myqorzo, Cytokinetics) commercially launched but still operationalizing its REMS program. Management reports physicians see little differentiation and that Camzyos' established REMS infrastructure (4+ years) and simpler dosing regimen are durable advantages. Implication: Competition is real but manageable near-term; Camzyos consensus of $357M for Q2 implies continued strong growth.
• Analyst Rating/PT Activity: No major rating changes identified in the post-Q1 window; consensus remains broadly constructive given the pipeline readout optionality and discounted valuation.

7. Peer Commentaries — Current-Quarter Read-Through

Filter applied: Only commentary from the last 60 days (May 30 – July 29, 2026) that was made after the peer's most recent earnings report and explicitly addresses Q2 2026 / current-quarter trends or an updated current-quarter outlook is included. Backward-looking Q1 2025 results commentary and pipeline-only updates with no current-quarter commercial read-through are excluded.

Johnson & Johnson (JNJ) — Goldman Sachs Healthcare Conference, June 9, 2026

Read-through relevance: HIGH (Milvexian partner; oncology/immunology overlap)

• Milvexian (direct BMY read-through): JNJ's Tom Cavanaugh expressed high confidence in milvexian, stating the company believes it will be a "$5 billion-plus asset" and that the AFib trial readout is event-driven and anticipated around year-end. JNJ's view that a 30–40% bleeding risk reduction would be needed to drive meaningful displacement of Eliquis provides a commercial framing for the opportunity. Implication for BMY: Partner confidence is unchanged and the commercial opportunity is large; the readout remains the single biggest binary event for BMY in 2026.
• Immunology — ICOTYDE (TYK2 inhibitor, direct Sotyktu competitor): JNJ reported ~4,500 prescribers in just 2 months of launch, with intent-to-prescribe and awareness up 20 points. Patient sourcing: ~60% systemic-naive, ~25% from oral therapies. DTC campaign expected soon. Implication for BMY: Competitive pressure on Sotyktu is real and accelerating; the systemic-naive sourcing suggests market expansion rather than pure switching, which is a partial offset, but BMY needs to monitor Sotyktu share trends closely.
• Oncology — RYBREVANT/LAZCLUZE: "1 in 4 patients" in the relevant NSCLC setting now receiving this combination; subcutaneous FASPRO permanent J-code effective July 1. Implication for BMY: Continued competitive pressure in NSCLC for Opdivo; J-code access improvements for competitors could accelerate share shifts.
• Overall pharma momentum: JNJ stated "'26 is going to be better than '25 and '27 is going to be better than '26" and is "well on the way" — a broadly positive read for the large-cap pharma operating environment in Q2 2026.

AbbVie (ABBV) — Goldman Sachs Healthcare Conference, June 9, 2026

Read-through relevance: MEDIUM (immunology/hematology overlap; BD landscape)

• U.S. pharma utilization — strong momentum: AbbVie reported "very strong momentum across the business" with top-line growth at ~10% reported and earnings growing >14% in 2026. SKYRIZI and RINVOQ growing at 23% each despite being 8 years on market. Implication for BMY: Positive read for the overall U.S. pharma demand environment in Q2 2026; suggests no macro-driven utilization headwinds.
• Hematology — Etentamig (BCMA TCE, multiple myeloma): AbbVie highlighted differentiated profile (outpatient, once-monthly, single step-up, CRS to 0% with single tocilizumab dose) and anticipates Phase III data later in 2026. Implication for BMY: Emerging competition in the BCMA space where BMY has Abecma; the differentiated convenience profile of etentamig could pressure BMY's cell therapy franchise longer-term.
• Drug pricing / gross-to-net environment: AbbVie flagged ongoing industry concerns around MFN codification, 340B abuse, and PBM reform. Management noted active advocacy to prevent MFN codification. Implication for BMY: Shared industry headwind; no incremental negative specific to BMY, but a reminder that pricing policy risk remains a sector-wide overhang.
• BD appetite: AbbVie clarified openness to later-stage and on-market opportunities, having deployed ~$8B in BD over the past 2+ years. Apogee Therapeutics acquisition ($10.9B) announced June 22, 2026. Implication for BMY: Active M&A environment; AbbVie's aggressive BD posture may increase competition for attractive assets BMY is also evaluating.

Merck (MRK) — Goldman Sachs Healthcare Conference, June 9, 2026

Read-through relevance: MEDIUM (oncology/PD-1 competitive landscape; BD)

• Oncology — KEYTRUDA + TRODELVY EVOKE trial discontinued: Merck confirmed the EVOKE trial (KEYTRUDA + TRODELVY in 1L NSCLC, PD-L1 high) was discontinued as it "didn't meet the bar." Implication for BMY: Reduces one competitive threat to Opdivo in NSCLC; the failure of this specific combination does not derisk the broader PD-1/VEGF bispecific competitive wave, but it is a modest positive for BMY's near-term NSCLC positioning.
• BD strategy: Merck reiterated its $1–15B deal sweet spot with focus on oncology, cardiometabolic, and immunology. Implication for BMY: Competitive BD landscape in BMY's core therapeutic areas; asset valuations may be elevated.
• Drug pricing / PBM reform: Merck highlighted that innovative drugs represent only 15% of total drug spend and 90% of prescriptions are generic, framing the PBM/340B reform debate. Implication for BMY: Consistent with AbbVie's commentary; no incremental negative for BMY specifically.

Pfizer (PFE) — Goldman Sachs Healthcare Conference, June 8, 2026

Read-through relevance: MEDIUM (oncology/PD-1 competitive landscape; pricing)

• PD-1/VEGF bispecific competitive threat: Pfizer CEO Albert Bourla stated that PD-1/VEGF bispecifics are "challenging the dominance" of PD-1 monotherapy and highlighted Pfizer's own 4404 program showing 77% response rate vs. KEYTRUDA's 45% and Summit's 60% in PD-L1 enriched populations. Implication for BMY: Significant medium-term competitive threat to Opdivo; BMY's own pumitamig (BNT327, PD-L1/VEGF bispecific) is in 7 pivotal studies and is the internal answer to this threat, but the competitive intensity in this class is accelerating.
• Non-COVID business performing well: Pfizer's non-COVID business grew 22% in Q1 2026 (new launches + BD portfolio at $3B, annualizing at $12B). Seagen portfolio +20% in Q1. Implication for BMY: Positive read for overall oncology market demand in Q2 2026; strong Seagen ADC performance validates the ADC opportunity that BMY is pursuing with iza-bren.
• U.S. pricing: Bourla noted U.S. drug prices "going down" broadly, while international markets (obesity) are cash-pay at high prices. Implication for BMY: Consistent with the gross-to-net headwind narrative; no incremental surprise.

Amgen (AMGN) — Goldman Sachs Healthcare Conference, June 9, 2026

Read-through relevance: LOW-MEDIUM (general pharma utilization; oncology)

• Overall 2026 momentum: Amgen CFO stated Q1 2026 was strong and 2026 is a "springboard year"; six key growth drivers grew 24% YoY in Q1 and represent 70% of product sales. Implication for BMY: Positive read for the large-cap biopharma operating environment in Q2 2026.
• Oncology — IMDELLTRA (SCLC bispecific): Now annualizing at >$1B in sales; established as standard of care in 2L SCLC with >1,800 sites of care, >50% in community settings. Implication for BMY: Demonstrates that novel oncology mechanisms can achieve rapid market penetration; validates the commercial opportunity for BMY's atigotatug (BMS-986012) in SCLC.

Gilead Sciences (GILD) — Goldman Sachs Healthcare Conference, June 9, 2026

Read-through relevance: LOW-MEDIUM (cell therapy/hematology competitive landscape)

• Cell therapy — Anito-cel (multiple myeloma): Gilead stated it is "very well prepared" to launch anito-cel in MM with 5x the ATC centers of prior CAR-T launches; 2L trial essentially fully enrolled. Implication for BMY: Intensifying competition for Abecma (ide-cel) in multiple myeloma; Gilead's broad ATC network and manufacturing confidence suggest a well-resourced competitive launch.
• Immunology — Ouro acquisition (CD3/BCMA bispecific for I&I): Gilead highlighted compelling early Phase I/II data in orphan I&I indications. Implication for BMY: Emerging competition in the autoimmune B-cell depletion space where BMY is building its arlo-cel/allogeneic CAR-T franchise.

AstraZeneca (AZN) — Q2 2026 Earnings, July 27, 2026

Read-through relevance: MEDIUM (oncology market demand; ADC competitive landscape)

• Q2 2026 oncology revenue +15% YoY: AZN reported strong Q2 2026 results driven by a 15% increase in oncology product sales and reiterated its 2030 revenue target. Implication for BMY: Strong positive read for oncology market demand in Q2 2026; suggests the overall oncology market environment was healthy in the quarter, which is supportive for Opdivo and the growth portfolio.
• Note — AZN trial failure (July 9): AZN shares fell 6% after a clinical trial failure, raising questions about pipeline premium. Implication for BMY: Reminder that pipeline execution risk is real and the market penalizes misses sharply; BMY's own late-2026 readout slate (milvexian, ADEPT, admilparant) carries similar binary risk.

Novartis (NVS) — Q2 2026 Earnings, July 21, 2026

Read-through relevance: LOW-MEDIUM (general pharma market; cardiovascular)

• Q2 2026 sales growth driven by key drugs; full-year guidance maintained: Novartis returned to sales growth in Q2 2026 on strong performance from key drugs and beat profit expectations. CEO Vas Narasimhan emphasized strategic pipeline investments and new launches. Implication for BMY: Positive read for the large-cap pharma operating environment in Q2 2026; new launches can drive meaningful growth even in a competitive market.

Johnson & Johnson (JNJ) — Q2 2026 Earnings, July 15, 2026

Read-through relevance: MEDIUM (pharma market demand; guidance raise)

• JNJ raised full-year guidance after strong Q2 results: JNJ beat Q2 earnings estimates on strong pharmaceutical sales (Tremfya outperformed) and raised full-year guidance, with CFO stating it's "just the start" of growth. Medtech missed on Impella pump challenges. Implication for BMY: Strong positive read for U.S. pharma demand in Q2 2026; JNJ's guidance raise and pharma outperformance suggest the market environment was favorable for BMY's commercial portfolio in the quarter.

8. Insider Transaction Activity

Key Takeaway: No open-market insider purchases or discretionary sales were identified for BMY in the post-Q1 window (April 30 – July 29, 2026). The absence of insider buying at current price levels (~$60–63) is notable given the stock's discount to peers, but the absence of selling is also a neutral-to-positive signal heading into a high-stakes pipeline readout period.

Source: SEC Form 4 Filings Database. Window: April 30 – July 29, 2026. Open-market transaction codes P (purchase) and S (sale) only.